We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Lays Out Initial DMF Assessment Requirements Under GDUFA
FDA Lays Out Initial DMF Assessment Requirements Under GDUFA
October 9, 2012
The FDA has outlined the requirements that drugmakers submitting Type II active pharmaceutical ingredient (API) drug master files (DMF) must meet before the files are listed on the agency’s public website as available for reference to support an ANDA.